First Time Loading...

Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 40.3 USD 1.21% Market Closed
Updated: May 3, 2024

Halozyme Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Halozyme Therapeutics Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Halozyme Therapeutics Inc
NASDAQ:HALO
Cash from Financing Activities
-$408m
CAGR 3-Years
-57%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$17.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$5.1B
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
$21B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
23%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$562.2m
CAGR 3-Years
-4%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.8B
CAGR 3-Years
3%
CAGR 5-Years
-88%
CAGR 10-Years
N/A

See Also

What is Halozyme Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
-408m USD

Based on the financial report for Dec 31, 2023, Halozyme Therapeutics Inc's Cash from Financing Activities amounts to -408m USD.

What is Halozyme Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-45%

The average annual Cash from Financing Activities growth rates for Halozyme Therapeutics Inc have been -57% over the past three years , -45% over the past five years .